Infographics - Hepatitis Drugs Market

Hepatitis refers to an inflammatory condition of the liver. Viral infections of the liver classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are most likely to become ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women which increase maternal and fetal mortality and morbidity.

Market Dynamics

Increasing prevalence of hepatitis worldwide is expected to boost growth of the hepatitis drugs market. According to World Health Organization (WHO), in 2015, 257 million people were living with chronic hepatitis B infection, and in 2016, while 4.5 million (16.7%) of the people were diagnosed with hepatitis B . Hepatitis B can be prevented by safe and effective vaccines. Additionally, the WHO aims for eliminating viral hepatitis infections which include 90% reduction of new infections, 65% reduction in deaths resulting from viral hepatitis infections worldwide by 2030.

However, factors such as longer development and approval time for hepatitis drugs is expected to hinder growth of the hepatitis drugs market during the forecast period. For instance, according to the National Center for Biotechnology Information 2017, the development of a new medicine for hepatitis from target identification through approval for marketing, takes 12 years or longer.

Key features of the study:

This report provides in-depth analysis of the hepatitis drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2027, considering 2018 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global hepatitis drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global hepatitis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hepatitis drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Hepatitis Drugs Market, By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
Global Hepatitis Drugs Market, By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
Global Hepatitis Drugs Market, By Route of Administration:
- Oral
- Injection
Global Hepatitis Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Hepatitis Drugs Market, By Region:
- North America
  - By Country:
    - U.S.
    - Canada
  - By Drug Class:
    - Interferon Alphas
    - HIV NRTIs
    - Nucleotide Polymerase / NS5A Inhibitor Combinations
    - Hepatitis C Protease / NS5A Inhibitor Combinations
    - NS5A Inhibitors
    - Nucleotide Polymerase Inhibitors
    - Nucleoside Analogue Antivirals
    - Thrombopoiesis Stimulating Agents
  - By Disease Type:
    - Hepatitis B
    - Hepatitis C
    - Others
  - By Route of Administration:
    - Oral
    - Injection
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Europe
  - By Country:
    - U.K.
    - Germany
    - Italy
    - Spain
    - France
    - Russia
    - Rest of Europe
  - By Drug Class:
    - Interferon Alphas
    - HIV NRTIs
    - Hepatitis B NRTIs
    - Nucleotide Polymerase / NS5A Inhibitor Combinations
    - Hepatitis C Protease / NS5A Inhibitor Combinations
    - NS5A Inhibitors
    - Nucleotide Polymerase Inhibitors
    - Nucleoside Analogue Antivirals
    - Thrombopoiesis Stimulating Agents
  - By Disease Type:
    - Hepatitis B
    - Hepatitis C
    - Others
  - By Route of Administration:
    - Oral
    - Injection
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Asia Pacific
  - By Country:
    - Australia
    - India
    - China
    - Japan
    - ASEAN
    - South Korea
    - Rest of Asia Pacific
  - By Drug Class:
    - Interferon Alphas
    - HIV NRTIs
    - Nucleotide Polymerase / NS5A Inhibitor Combinations
    - Hepatitis C Protease / NS5A Inhibitor Combinations
    - NS5A Inhibitors
    - Nucleotide Polymerase Inhibitors
    - Nucleoside Analogue Antivirals
    - Thrombopoiesis Stimulating Agents
  - By Disease Type:
    - Hepatitis B
    - Hepatitis C
    - Others
  - By Route of Administration:
    - Oral
    - Injection
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Latin America
  - By Country:
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
  - By Drug Class:
    - Interferon Alphas
    - HIV NRTIs
    - Nucleotide Polymerase / NS5A Inhibitor Combinations
    - Hepatitis C Protease / NS5A Inhibitor Combinations
    - NS5A Inhibitors
    - Nucleotide Polymerase Inhibitors
    - Nucleoside Analogue Antivirals
    - Thrombopoiesis Stimulating Agents
  - By Disease Type:
    - Hepatitis B
    - Hepatitis C
    - Others
  - By Route of Administration:
    - Oral
    - Injection
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Middle East
  - By Country:
    - GCC
    - Israel
    - Rest of Middle East
  - By Drug Class:
    - Interferon Alphas
    - HIV NRTIs
    - Nucleotide Polymerase / NS5A Inhibitor Combinations
    - Hepatitis C Protease / NS5A Inhibitor Combinations
    - NS5A Inhibitors
    - Nucleotide Polymerase Inhibitors
    - Nucleoside Analogue Antivirals
    - Thrombopoiesis Stimulating Agents
  - By Disease Type:
    - Hepatitis B
    - Hepatitis C
    - Others
  - By Route of Administration:
    - Oral
    - Injection
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Africa
  - By Country:
    - South Africa
    - Central Africa
    - North Africa
  - By Drug Class:
    - Interferon Alphas
    - HIV NRTIs
    - Nucleotide Polymerase / NS5A Inhibitor Combinations
    - Hepatitis C Protease / NS5A Inhibitor Combinations
    - NS5A Inhibitors
    - Nucleotide Polymerase Inhibitors
    - Nucleoside Analogue Antivirals
    - Thrombopoiesis Stimulating Agents
  - By Disease Type:
    - Hepatitis B
    - Hepatitis C
    - Others
  - By Route of Administration:
    - Oral
    - Injection
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
Company Profiles
- Merck & Co. Inc.*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Gilead Sciences Inc.
AbbVie Inc.
Bristol Myers Squibb Company
Hoffmann-La Roche Ltd.
LAURUS Labs
Zydus Cadila
Hetero Healthcare Limited
GlaxoSmithKline PLC
Cipla Inc.

“*” marked represents similar segmentation in other categories in the respective section

Table of Contents

Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

Market Overview

Report Description

Market Definition and Scope

Executive Summary

Market Snippet, By Drug Class
Market Snippet, By Disease Type
Market Snippet, By Route of Administration
Market Snippet, By Distribution Channel
Market Snippet, By Region

Coherent Opportunity Map (COM)

Market Dynamics, Regulations, and Trends Analysis

Market Dynamics

Drivers
Restraints
Market Opportunities

Impact Analysis
Market Trends
Key Developments
Regulatory Landscape
Epidemiology Analysis
Reimbursement Scenario
PEST Analysis

Global Hepatitis Drugs Market, By Drug Class, 2019 – 2027 (US$ Million)

Introduction

Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017 – 2027
Segment Trends

Interferon Alphas

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

HIV NRTIs

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

Nucleotide Polymerase / NS5A Inhibitor Combinations

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

Hepatitis C Protease / NS5A Inhibitor Combinations

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

NS5A Inhibitors

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

Nucleotide Polymerase Inhibitors

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

Nucleoside Analogue Antivirals

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

Thrombopoiesis Stimulating Agents

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

Global Hepatitis Drugs Market, By Disease Type, 2019 – 2027, (US$ Million)

Introduction

Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017 – 2027
Segment Trends

Hepatitis B

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

Hepatitis C

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

Others

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

Global Hepatitis Drugs Market, By Route of Administration, 2019 – 2027, (US$ Million)

Introduction

Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017 – 2027
Segment Trends

Oral

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

Injection

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

Global Hepatitis Drugs Market, By Distribution Channel, 2019 – 2027, (US$ Million)

Introduction

Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017 – 2027
Segment Trends

Hospital Pharmacies

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

Retail Pharmacies

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

Online Pharmacies

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

Global Hepatitis Drugs Market, By Region, 2019 – 2027, (US$ Million)

Introduction

Market Share Analysis, By Region, 2019 and 2027 (%)
Y-o-Y Growth Analysis, By Region, 2017 – 2027
Regional Trends

North America

Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)

U.S.
Canada

Europe

Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe

Asia Pacific

Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)

China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific

Latin America

Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)

Brazil
Mexico
Argentina
Rest of Latin America

Africa

Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)

North Africa
Central Africa
South Africa

Middle East

Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)l
Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)

GCC Countries
Israel
Rest of Middle East

Competitive Landscape

Company Profiles

Merck & Co. Inc.

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Gilead Sciences Inc.

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

AbbVie Inc.

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Bristol Myers Squibb Company

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

F. Hoffmann-La Roche Ltd.

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

LAURUS Labs

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Zydus Cadila

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Hetero Healthcare Limited

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

GlaxoSmithKline PLC.

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Cipla Inc.

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Analyst Views

Section

References
Research Methodology
About Us and Sales Contact

*Browse 35 market data tables and 27 figures on "Global Hepatitis Drugs Market” - Global forecast to 2026”

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount